Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Response to: 'Comment on: 'Treatment patterns and long-term outcomes in anti-VEGF-treated macular oedema secondary to retinal vein occlusion: a retrospective observational study".

Eye (London, England)·2026
Same author

The impact of an educational podcast on emotional wellbeing and attitudes towards Charles Bonnet syndrome hallucinations.

Therapeutic advances in ophthalmology·2026
Same author

Location of visual field defects and their impact on vision-related quality of life in glaucoma: A systematic review.

Optometry and vision science : official publication of the American Academy of Optometry·2026
Same author

Longitudinal Visual Field and Quality-of-Life Change in the Treatment for Advanced Glaucoma Study.

Ophthalmology·2026
Same author

Faricimab in Treatment-Naïve nAMD: Regional UK Real-World Experience.

Advances in therapy·2026
Same author

Defining a standards framework for ophthalmology real-world data methodologies through an expert-led Delphi consensus.

Eye (London, England)·2026

Related Experiment Video

Updated: Jan 6, 2026

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report
10:24

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report

Published on: February 12, 2018

10.7K

Patient-Reported Importance of Functional Benefit in Geographic Atrophy.

Christiana Dinah1,2, Jamie Enoch3, Arevik Ghulakhszian1

  • 1Ophthalmology Department, Central Middlesex Hospital, London North West University Healthcare National Health Service Trust, London, United Kingdom.

JAMA Ophthalmology
|September 25, 2025
PubMed
Summary
This summary is machine-generated.

Intravitreal complement inhibitor injections (IVCIs) are acceptable to most UK patients with geographic atrophy (GA) if vision benefits are expected. Patient belief in treatment effectiveness and regular clinic attendance positively correlated with acceptability.

More Related Videos

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential
07:11

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential

Published on: May 25, 2020

6.8K
Author Spotlight: Insights into Visual Cortex Research Through Wide-View fMRI Mapping
07:11

Author Spotlight: Insights into Visual Cortex Research Through Wide-View fMRI Mapping

Published on: December 8, 2023

2.3K

Related Experiment Videos

Last Updated: Jan 6, 2026

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report
10:24

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report

Published on: February 12, 2018

10.7K
Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential
07:11

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential

Published on: May 25, 2020

6.8K
Author Spotlight: Insights into Visual Cortex Research Through Wide-View fMRI Mapping
07:11

Author Spotlight: Insights into Visual Cortex Research Through Wide-View fMRI Mapping

Published on: December 8, 2023

2.3K

Area of Science:

  • Ophthalmology
  • Medical Therapeutics
  • Patient-Reported Outcomes

Background:

  • Intravitreal complement inhibitors injections (IVCIs) have shown promise in slowing geographic atrophy (GA) progression in clinical trials.
  • However, these treatments have not demonstrated significant benefits for secondary functional vision outcomes.
  • Patient acceptability of IVCIs requires further investigation, particularly concerning perceived benefits.

Purpose of the Study:

  • To quantify the acceptability of IVCI therapy among United Kingdom patients diagnosed with GA.
  • To assess patient expectations regarding vision outcome benefits associated with IVCI treatment.
  • To explore factors influencing patient acceptability of IVCI therapy for GA.

Main Methods:

  • A cross-sectional study was conducted across 9 UK National Health Service centers.
  • 153 treatment-naive participants with GA were recruited between April 2023 and April 2024.
  • Acceptability was measured using a validated questionnaire, alongside the EuroQol 5-dimension with a vision bolt-on for quality of life assessment.

Main Results:

  • Over half of participants (53%) found IVCIs very much or extremely acceptable under theoretical scenarios.
  • Acceptability increased to 82% when including moderately acceptable responses.
  • Perceived treatment effectiveness (ρ=0.52) and confidence in regular clinic attendance (ρ=0.51) significantly correlated with overall acceptability.

Conclusions:

  • IVCI therapy for GA is likely acceptable to a majority of UK patients, provided there is an expectation of vision outcome benefits.
  • Patient-reported perceived effectiveness is a key driver of acceptability, highlighting the need to align anatomical benefits with functional vision improvements.
  • Findings underscore the importance of patient perspectives in the adoption of new ophthalmic therapies for GA.